

Processing text_000N_17660.tx.1: CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.

Phrase: CD19

>>>> Phrase

cd19

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 CD19+ (CD19 Positive {NCI}) [lbtr]

<<<< Mappings

Phrase: targeted

>>>> Phrase

targeted

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Targeted (Target {MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: CAR-T therapy

>>>> Phrase

car t therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (802):

660 Car (Automobiles

{AOD,CHV,LCH,LCH_NW,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [mnob]

827 Therapy (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})

[topp]

<<<< Mappings

Phrase: versus

>>>> Phrase

<<<< Phrase

Phrase: chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia

>>>> Phrase

chemotherapy in re induction treatment of refractory relapsed acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (764):

738 Chemotherapy (Pharmacotherapy

{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-

```
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
  571 {RE} (Retinol equivalents {CHV,MTH,NCI,NCI_UCUM,SNOMEDCT_US})
[qnco]
  589 INDUCTION TREATMENT (Induction Therapy Epoch
{MTH,NCI,NCI_CDISC}) [resa]
  571 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
  630 Acute lymphoblastic leukemia, in relapse {ICD10CM} [neop]
<<<< Mappings
```

```
Phrase: :
>>>> Phrase
<<<< Phrase
```

Phrase: results of a case-controlled study.

```
>>>> Phrase
results of a case controlled study
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (764):

```
  719 Result (Experimental Result {MTH,NCI,NLMSubSyn}) [fndg]
  655 Case-Control Study (Case-Control Studies
{AOD,CHV,CSP,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [resa]
<<<< Mappings
Processing text_000N_10353.tx.1: Chimeric antigen receptor modified T
cells against CD19 (CART19s) have potent anti-leukemia activities in
patients with refractory/relapsed acute lymphoblastic leukemia (R/R
ALL).
```

Phrase: Chimeric antigen receptor

```
>>>> Phrase
chimeric antigen receptor
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
  1000 Chimeric Antigen Receptor (Chimeric antigen receptor
{MTH,NCI,SNOMEDCT_US}) [aapp,imft,rcpt]
<<<< Mappings
```

Phrase: modified

```
>>>> Phrase
```

```
modified
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
  1000 Modified (Changing
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings
```

Phrase: T cells against CD19

```
>>>> Phrase
t cells against cd19
<<<< Phrase
>>>> Mappings
Meta Mapping (819):
  819  Cells.CD19 (Cell positive for CD19 antigen {LNC,SNOMEDCT_US})
  [cell]
<<<< Mappings

Phrase: (CART19s
>>>> Phrase
cart19s
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: potent anti-leukemia activities in patients
>>>> Phrase
potent anti leukemia activities in patients
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  586  LEUKEMIA (leukemia
  {AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH
  _NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-
  SDC,NCI_NCI-GLOSS,NCI_NICHHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
  [neop]
    753  Activities
  {CHV,ICD9CM,LNC,MTH,NCI,NCI_BRIDG,NLMSubSyn,SNOMEDCT_US} [acty]
      586  Patients
  {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
  A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: with refractory/relapsed acute lymphoblastic leukemia (R/R
ALL).
>>>> Phrase
refractory relapsed acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (875):
  637  Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
  GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
      637  relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
```

884 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDSC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings
Processing text_000N_10353.tx.2: This study was designed to
investigate the correlation between safety/efficacy and therapeutic
modalities including chemotherapy and CART19 therapy.

Phrase: This study
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: designed
>>>> Phrase
designed
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Design {MTH,NCI} [acty]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: investigate
>>>> Phrase
investigate
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 investigate (Investigates {CHV,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the correlation between safety/efficacy

>>>> Phrase
the correlation between safety efficacy

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

 760 Correlation {MTH,NCI} [qlco]
 593 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
 593 EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: therapeutic modalities

>>>> Phrase
therapeutic modalities

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Therapeutic (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

 861 modalities (Modality {CHV,LNC,MTH,NCI,NCI_DICOM,NCI_NCI-
 GLOSS,NCI_NICHHD}) [idcn]

<<<< Mappings

Phrase: including

>>>> Phrase
including

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Including (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})
[ftcn]

<<<< Mappings

Phrase: chemotherapy

>>>> Phrase
chemotherapy

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Chemotherapy (Pharmacotherapy
 {AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [topp]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: CART19 therapy.

>>>> Phrase

cart19 therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes {NCI}) [cell]
861 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Processing text_000N_10353.tx.3: Total 23 and 69 patients were enrolled in the CART19 group and in the chemotherapy group, respectively.

Phrase: Total 23

>>>> Phrase

total 23

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

861 Total {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
861 23 {MTH,NCI,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: 69 patients

>>>> Phrase

69 patients

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 69 {NCI,SNOMEDCT_US} [qnco]
861 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: were

>>>> Phrase
<<<< Phrase

Phrase: enrolled in the CART19 group
>>>> Phrase
enrolled in the cart19 group
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
 760 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes {NCI}) [cell]
 760 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: and in the chemotherapy group,
>>>> Phrase
and in the chemotherapy group
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
 760 Chemotherapy (Pharmacotherapy {AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
 760 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: respectively.
>>>> Phrase
respectively
<<<< Phrase
Processing text_000N_10353.tx.4: The safety and efficacy profiles of 66 and 22 patients in the 2 groups were evaluated.

Phrase: The safety
>>>> Phrase
safety
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: efficacy profiles of 66
>>>> Phrase
efficacy profiles of 66
<<<< Phrase

```
>>>> Mappings
Meta Mapping (722):
  604  EFFICACY (Efficacy Study {MTH,NCI,NCI_CDISC,NLMSubSyn})
[resa]
  737  Profile (Profile (lab procedure) {LNC,MTH}) [lbpr]
  604  66 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 22 patients in the 2 groups
>>>> Phrase
22 patients in the 2 groups
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
  753  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
  617  Group 2 {MTH,NLMSubSyn,SNOMEDCT_US} [inpr]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: evaluated.
>>>> Phrase
evaluated
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Evaluated (Evaluation
{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICH,NLMSubSyn}) [hlca]
<<<< Mappings
Processing text_000N_10353.tx.5: The complete remission (CR) rate was
higher in the CART19 group than that in the chemotherapy group (90.9
vs 37.9%, P0.0).

Phrase: The complete remission (CR) rate
>>>> Phrase
complete remission rate
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
  901  Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fndg]
```

827 Rate {LNC,MTH,NCI} [qnco]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: higher in the CART19 group

>>>> Phrase
higher in the cart19 group
<<<< Phrase

>>>> Mappings

Meta Mapping (696):

760 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
593 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
593 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]

<<<< Mappings

Phrase: than that in the chemotherapy group

>>>> Phrase
than that in the chemotherapy group
<<<< Phrase

>>>> Mappings

Meta Mapping (679):

753 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
753 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]

<<<< Mappings

Phrase: (90.9

>>>> Phrase

90 9

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 <90 {SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: vs

>>>> Phrase

<<<< Phrase

Phrase: 37.9%,

>>>> Phrase

37 9

<<<< Phrase

Phrase: P0.0

```
>>>> Phrase
p0 0
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 861 P0 (RPLP0 gene {HGNC,MTH,NLMSubSyn,OMIM}) [gngm]
 861 0% {LNC} [qnco]
<<<< Mappings

Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_10353.tx.6: For patients relapsed after allo-HSCT
and chemotherapy, CR rates were 100% (8/8) vs 48.0% (12/25) (P=0.009)
and 85.7% (12/14) vs 31.7% (13/41) (P=0.000), respectively.

Phrase: For patients
>>>> Phrase
patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: relapsed after allo-HSCT
>>>> Phrase
relapsed after allo hsct
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 770 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
 770 ALLO (Allopurinol
{ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTHSPL,NCI,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
 770 HSCT (Allogeneic Hematopoietic Stem Cell Transplantation
{MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,PDQ}) [topp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: chemotherapy,
>>>> Phrase
chemotherapy
<<<< Phrase
>>>> Mappings
```

Meta Mapping (1000):
1000 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: CR rates
>>>> Phrase
complete remission rates
<<<< Phrase
>>>> Mappings

Meta Mapping (884):
901 Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fnndg]
793 Rate {LNC,MTH,NCI} [qnco]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: 100%
>>>> Phrase
100
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 100% {LNC,MTH} [qnco]
<<<< Mappings

Phrase: (8/8
>>>> Phrase
8 8
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 8.8 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: vs
>>>> Phrase
<<<< Phrase

Phrase: 48.0%
>>>> Phrase

48 0
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 861 48 {MTH,SNOMEDCT_US} [qnco]
 861 0% {LNC} [qnco]
<<<< Mappings

Phrase: (12/25
>>>> Phrase
12 25
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: (P=0.009
>>>> Phrase
p 0 009
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 827 P NOS (P Blood group antibodies
 {CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
 827 0% {LNC} [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 85.7%
>>>> Phrase
85 7
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 85 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: (12/14
>>>> Phrase
12 14
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: vs
>>>> Phrase
<<<< Phrase

Phrase: 31.7%
>>>> Phrase
31 7
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 31 {MTH,NCI,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: (13/41
>>>> Phrase
13 41
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: (P=0.000
>>>> Phrase
p 0 000
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 827 P NOS (P Blood group antibodies
 {CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
 827 0% {LNC} [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: respectively.
>>>> Phrase
respectively
<<<< Phrase

Processing text_000N_10353.tx.7: Moreover, a higher percentage in the

CART19 group had results below the threshold for minimal residual disease (100 vs 7.58%, P=0.000).

Phrase: Moreover,

>>>> Phrase

moreover

<<<< Phrase

Phrase: a higher percentage in the CART19 group

>>>> Phrase

a higher percentage in the cart19 group

<<<< Phrase

>>>> Mappings

Meta Mapping (710):

581 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

748 Percentage (Percent (qualifier value)

{CHV,HL7V2.5,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_ICH,NCI_NCI-HL7,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [qnco]

581 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes {NCI}) [cell]

607 Group A {CHV,SNOMEDCT_US} [clas]

<<<< Mappings

Phrase: had

>>>> Phrase

<<<< Phrase

Phrase: results below the threshold

>>>> Phrase

results below the threshold

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US} [ftcn]

770 THRESHOLD (Threshold {CHV,LNC,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: for minimal residual disease

>>>> Phrase

minimal residual disease

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Minimal Residual Disease (Neoplasm, Residual {CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]

<<<< Mappings

Phrase: (100

>>>> Phrase

100

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  100% {LNC,MTH} [qnco]
<<<< Mappings

Phrase: vs
>>>> Phrase
<<<< Phrase

Phrase: 7.58%,
>>>> Phrase
7 58
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861  58 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: P=0.000
>>>> Phrase
p 0 000
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 827  P NOS (P Blood group antibodies
{CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
 827  0% {LNC} [qnco]
<<<< Mappings

Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_10353.tx.8: In survival analysis, the overall
survival rate at 12months was higher in the CART19 group than that in
the chemotherapy group (60.9 vs 10.1%, P=0.000).

Phrase: In survival analysis,
>>>> Phrase
survival analysis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Survival Analysis {CHV,MSH,NCI,NLMSubSyn} [resa]
<<<< Mappings

Phrase: the overall survival rate at 12months
>>>> Phrase
the overall survival rate at 12months
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (833):
  833  overall survival rate (Survival Rate {CHV,MSH,NCI,NCI_NCI-
GLOSS,NLMSubSyn}) [qnco]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: higher in the CART19 group
>>>> Phrase
  higher in the cart19 group
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  760  Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
  593  CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
  593  Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: than that in the chemotherapy group
>>>> Phrase
  than that in the chemotherapy group
<<<< Phrase
>>>> Mappings
Meta Mapping (679):
  753  Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
  753  Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: (60.9
>>>> Phrase
  60 9
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
  861  60% {LNC} [qnco]
<<<< Mappings

Phrase: vs
>>>> Phrase
<<<< Phrase

Phrase: 10.1%,
>>>> Phrase
  10 1
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
    861  10% {LNC} [qnco]
<<<< Mappings

Phrase: P=0.000
>>>> Phrase
p 0 000
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
    827  P NOS (P Blood group antibodies
{CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
    827  0% {LNC} [qnco]
<<<< Mappings

Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_10353.tx.9: For post-transplant patients
achieving CR, 25.0% (2/8) and 75.0% (9/12) complicated with GVHD
(P=0.04) in the CART19 group and chemotherapy group, respectively.

Phrase: For post-transplant patients
>>>> Phrase
post transplant patients
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
    660  Post {CHV,LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US} [tmco]
    660  Transplant (Transplantation
{AOD,CHV,CSP,LCH,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [topp]
    827  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: achieving
>>>> Phrase
achieving
<<<< Phrase

Phrase: CR,
>>>> Phrase
complete remission
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

1000 Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fnndg]
<<<< Mappings

Phrase: 25.0%
>>>> Phrase
25 0
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 0% {LNC} [qnco]
<<<< Mappings

Phrase: (2/8
>>>> Phrase
2 8
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 2+ (2+ Score, WHO {MTH,NCI}) [clas]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 75.0%
>>>> Phrase
75 0
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 861 75 {MTH,SNOMEDCT_US} [qnco]
 861 0% {LNC} [qnco]
<<<< Mappings

Phrase: (9/12
>>>> Phrase
9 12
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: complicated with GVHD
>>>> Phrase
complicated with gvhd
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 Complicated {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [ftcn]
<<<< Mappings

Phrase: (P=0.04
>>>> Phrase
p 0 04
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 827 P NOS (P Blood group antibodies
{CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
 901 0.04 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: in the CART19 group
>>>> Phrase
cart19 group
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
 861 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: chemotherapy group,
>>>> Phrase
chemotherapy group
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
 861 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: respectively.

>>>> Phrase
respectively
<<<< Phrase

Processing text_000N_10353.tx.10: For all CR patients, the median duration of absolute neutrophil count less than 500/L and platelet count less than 20,000/L were longer in the CART19 group than in the chemotherapy group ($p=0.0047$ and 0.0003 , respectively).

Phrase: For all CR patients,

>>>> Phrase
complete remission patients
<<<< Phrase

>>>> Mappings

Meta Mapping (901):

 734 Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
 [fndg]

 827 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: the median duration of absolute neutrophil count less

>>>> Phrase
the median duration of absolute neutrophil count less
<<<< Phrase

>>>> Mappings

Meta Mapping (724):

 578 Median (Median Statistical Measurement
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [qnc0]

 744 Duration (Duration (temporal concept)
{CHV,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]

 633 Absolute Neutrophil Count (Absolute neutrophil count
{CHV,MTH,NCI,NCI_CDISC,NLMSubSyn}) [lbpr]

<<<< Mappings

Phrase: than 500/L

>>>> Phrase
500 l
<<<< Phrase

>>>> Mappings

Meta Mapping (694):

 694 500 {LNC,MTH,SNOMEDCT_US} [qnc0]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: platelet count less than 20,000/L
>>>> Phrase
platelet count less than 20 000 l
<<<< Phrase
>>>> Mappings
Meta Mapping (706):
 778 Platelet Count (Platelet Count measurement
 {AOD,CHV,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]
 581 20% {LNC} [qnco]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: longer in the CART19 group
>>>> Phrase

longer in the cart19 group
<<<< Phrase
>>>> Mappings
Meta Mapping (685):
 726 LONG (Long {CHV,MTH,NCI,NCI_CDISC,OMIM,SNMI,SNOMEDCT_US})
 [qlco]
 593 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
 lymphocytes {NCI}) [cell]
 593 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: than in the chemotherapy group
>>>> Phrase

than in the chemotherapy group
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
 760 Chemotherapy (Pharmacotherapy
 {AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
 760 Group (User Group {MTH,NCI,NLMSubSyn}) [popg]
<<<< Mappings

Phrase: (p=0.0047
>>>> Phrase
p 0 0047
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 827 P NOS (P Blood group antibodies
 {CHV,LNC,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [aapp,imft]
 827 0% {LNC} [qnco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: 0.0003,

>>>> Phrase

0 0003

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 0% {LNC} [qnco]

<<<< Mappings

Phrase: respectively

>>>> Phrase

respectively

<<<< Phrase

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_10353.tx.11: Our data demonstrated that patients with CART19s therapy acquired higher rates of remission and longer survival, confirming the encouraging application of CART19 therapy in R/R ALL.

Phrase: Our data

>>>> Phrase

data

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Data {MTH,NCI} [idcn]

<<<< Mappings

Phrase: demonstrated

>>>> Phrase

demonstrated

<<<< Phrase

Phrase: that patients with CART19s therapy

>>>> Phrase

that patients with cart19s therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (686):

760 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD

A,SNOMEDCT_US} [podg]
593 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHID,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: acquired
>>>> Phrase
acquired
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Acquired (Acquired (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: higher rates of remission
>>>> Phrase
higher rates of remission
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
604 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
737 Rate {LNC,MTH,NCI} [qnco]
604 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: longer survival,
>>>> Phrase
longer survival
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
661 LONG (Long {CHV,MTH,NCI,NCI_CDISC,OMIM,SNMI,SNOMEDCT_US})
[qlco]
861 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: confirming
>>>> Phrase
confirming
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 confirming (Confirmation {CHV,LNC,MTH,NCI}) [fndg]
<<<< Mappings

Phrase: the encouraging application of CART19 therapy

>>>> Phrase

the encouraging application of cart19 therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (672):

753 Application (Regulatory Application
{MTH,NCI,NCI_BRIDG,NCI_FDA}) [inpr]
586 CART19 (CD19CAR-CD3zeta-4-1BB-expressing Autologous T-
lymphocytes {NCI}) [cell]
586 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: in R/R ALL.

>>>> Phrase

refractory relapsed acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (875):

637 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [ftcn]
637 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
884 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDISC,N
CI_CTEP-SDC,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDQ,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET})
[neop]
<<<< Mappings

Processing text_000N_44116.tx.1: PMID: 29417201 [Indexed for MEDLINE]

Phrase: PMID

>>>> Phrase

pmid

<<<< Phrase

Phrase: :

>>>> Phrase

<<<< Phrase

Phrase: 29417201

>>>> Phrase

29417201

<<<< Phrase

```
Phrase: [Indexed for MEDLINE
>>>> Phrase
indexed for medline
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790 indexed (Index {CHV,MSH,MTH,NCI}) [inpr]
  623 MEDLINE {CHV,LCH_NW,MSH,MTH} [inpr]
<<<< Mappings

Phrase: ]
>>>> Phrase
<<<< Phrase
Processing text_000N_22471.tx.1: Deletion analysis of p16(INKa) and
p15(INKb) in relapsed childhood acute lymphoblastic leukemia.

Phrase: Deletion analysis of p16
>>>> Phrase
deletion analysis of p16
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
  833 Deletion analysis (Gene deletion analysis
{NLMSubSyn,SNOMEDCT_US}) [lbpr]
  604 P16 (CDKN2A wt Allele {MTH,NCI,NLMSubSyn}) [gngm]
<<<< Mappings

Phrase: (INKa
>>>> Phrase
inka
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 INKA (neurokinin A, iodoHis(3)- {MSH}) [aapp,irda]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: p15
>>>> Phrase
p15
<<<< Phrase
```

Phrase: (INKb
>>>> Phrase
inkb
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: in relapsed childhood acute lymphoblastic leukemia.
>>>> Phrase
relapsed childhood acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 relapsed childhood Acute lymphoblastic leukaemia (recurrent childhood acute lymphoblastic leukemia {CHV,NCI,NLMSubSyn,PDQ}) [neop]
<<<< Mappings
Processing text_000N_42449.tx.1: This study aimed at determining the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction.

Phrase: This study
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: aimed at determining
>>>> Phrase
aimed at determining
<<<< Phrase
>>>> Mappings
Meta Mapping (756):
756 Aim (Aim (idea) {MTH,NCI}) [idcn]
<<<< Mappings

Phrase: the prevalence of INK4 deletions
>>>> Phrase
the prevalence of ink4 deletions
<<<< Phrase
>>>> Mappings
Meta Mapping (685):
760 prevalence (Prevalence aspects {MSH,MTH}) [qnco]
593 INK4 (CDKN2A wt Allele {MTH,NCI,NLMSubSyn}) [gngm]
560 Deletion (Deletion (action) {MTH,NCI}) [acty]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: their impact on outcome

>>>> Phrase

their impact on outcome

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 IMPACT (IMPACT gene {HGNC,MTH,OMIM}) [gngm]

604 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: in 125 children with acute lymphoblastic leukemia

>>>> Phrase

in 125 children with acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (795):

581 ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDSC,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [tmco]

831 Lymphoblastic leukemia in children {LCH_NW} [neop]

<<<< Mappings

Phrase: at first

>>>> Phrase

first

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 First (First (number) {CHV,LNC,MTH,SNOMEDCT_US}) [qnc0]

<<<< Mappings

Phrase: relapse

>>>> Phrase

relapse

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: using

>>>> Phrase

using

<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  Using (Use of {MTH,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: real-time quantitative polymerase chain reaction.
>>>> Phrase
  real time quantitative polymerase chain reaction
<<<< Phrase
>>>> Mappings
Meta Mapping (938):
  929  Real Time Polymerase Chain Reaction (Real-Time Polymerase
Chain Reaction {MSH,MTH,NCI,NCI_CDISC,NLMSubSyn}) [mbrt]
  799  Quantitative {CHV,NCI,NCI_NICHD,SNMI,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_42449.tx.2: Patients were enrolled into relapse
trials ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Mnster) 90 and 96.

Phrase: Patients
>>>> Phrase
  patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: enrolled into relapse trials ALL-REZ BFM
>>>> Phrase
  enrolled into relapse trials acute lymphoblastic leukemia rez bfm
<<<< Phrase
>>>> Mappings
Meta Mapping (766):
  708  Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NC
I-GLOSS,SNOMEDCT_US}) [resal]
  810  Acute lymphoblastic Leukemia relapse (Acute lymphoblastic
leukemia recurrent {MTH,NLMSubSyn}) [neop]
<<<< Mappings

Phrase: (ALL-Relapse Berlin-Frankfurt-Mnster
>>>> Phrase
  acute lymphoblastic leukemia relapse berlin frankfurt mnster
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (710):
  710  Acute lymphoblastic Leukemia relapse (Acute lymphoblastic
leukemia recurrent {MTH,NLMSubSyn}) [neop]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: 90
>>>> Phrase
90
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  <90 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 96.
>>>> Phrase
96
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  96 {MTH,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_42449.tx.3: The prevalence of p16(INK4a) and
p15(INK4b) homozygous deletions was 35% (44 of 125) and 30% (38 of
125), respectively.

Phrase: The prevalence of p16
>>>> Phrase
the prevalence of p16
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
  770  prevalence (Prevalence aspects {MSH,MTH}) [qnco]
  604  p16 (CDKN2A gene {CHV,HGNC,LNC,MSH,MTH,NCI,NCI_NCI-
HGNC,NLMSubSyn,OMIM,PDQ}) [gnqm]
<<<< Mappings

Phrase: (INK4a
>>>> Phrase
ink4a
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (1000):
  1000  INK4A (CDKN2A wt Allele {MTH,NCI,NLMSubSyn}) [gngm]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: p15
>>>> Phrase
p15
<<<< Phrase

Phrase: (INK4b
>>>> Phrase
ink4b
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  INK4B (CDKN2B gene {CHV,HGNC,LNC,MTH,NCI,NCI_NCI-
HGNC,NLMSubSyn,OMIM}) [gngm]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: homozygous deletions
>>>> Phrase
homozygous deletions
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
  694  Homozygote (Homozygote {AOD,CHV,CSP,LNC,MSH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [orga]
  827  Deletion (Deletion (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: 35%
>>>> Phrase
35
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  35 {MTH,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: (44 of 125
>>>> Phrase
44 of 125
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 30%
>>>> Phrase
30
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  30% {LNC} [qnco]
<<<< Mappings

Phrase: (38 of 125
>>>> Phrase
38 of 125
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: respectively.
>>>> Phrase
respectively
<<<< Phrase
Processing text_000N_42449.tx.4: A highly significant association of both gene deletions was found with the 2 major adverse prognostic factors known for relapsed childhood ALL: T-cell immunophenotype and first remission duration.
```

Phrase: A highly significant association of both gene deletions

>>>> Phrase

a highly significant association of both gene deletions

<<<< Phrase

>>>> Mappings

Meta Mapping (706):

604 Highly significant {NLMSubSyn,SNOMEDCT_US} [qlco]

744 Association (Relationships

{CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

604 Gene Deletions (Gene Deletion

{CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [genf]

<<<< Mappings

Phrase: was

>>>> Phrase

<<<< Phrase

Phrase: found with the 2 major adverse prognostic factors

>>>> Phrase

found with the 2 major adverse prognostic factors

<<<< Phrase

>>>> Mappings

Meta Mapping (677):

744 Found (Present {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})

[fnndg]

744 Major {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

770 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]

<<<< Mappings

Phrase: known for relapsed childhood ALL

>>>> Phrase

known for relapsed childhood acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (862):

748 Known {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

897 relapsed childhood Acute lymphoblastic leukaemia (recurrent

childhood acute lymphoblastic leukemia {CHV,NCI,NLMSubSyn,PDQ}) [neop]

<<<< Mappings

Phrase: :

>>>> Phrase

<<<< Phrase

Phrase: T-cell immunophenotype

>>>> Phrase

t cell immunophenotype

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

734 T Cell (T-Lymphocyte
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
827 Immunophenotype (Immunophenotyping
{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: first remission duration.

>>>> Phrase
first remission duration
<<<< Phrase
>>>> Mappings

Meta Mapping (851):

660 First (First (number) {CHV,LNC,MTH,SNOMEDCT_US}) [qnc0]
660 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
827 Duration (Duration (temporal concept)
{CHV,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Processing text_000N_42449.tx.5: There was no correlation between INK4 deletions and probability of event-free survival.

Phrase: There
>>>> Phrase
there
<<<< Phrase

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: no correlation between INK4 deletions

>>>> Phrase
no correlation between ink4 deletions
<<<< Phrase
>>>> Mappings

Meta Mapping (685):
760 Correlation {MTH,NCI} [qlco]
593 INK4 (CDKN2A wt Allele {MTH,NCI,NLMSubSyn}) [gngm]
560 Deletion (Deletion (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: probability of event-free survival.
>>>> Phrase
probability of event free survival
<<<< Phrase
>>>> Mappings
Meta Mapping (816):
760 Probability {CHV,LCH_NW,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_FDA}
[qnco]
695 Event-Free Survival (Disease-Free Survival
{CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

<<<< Mappings
Processing text_000N_42449.tx.6: These findings argue against an independent prognostic role of INK4 deletions in relapsed childhood ALL.

Phrase: These findings
>>>> Phrase
findings
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Findings (Procedure findings:Finding:Point in
time:^Patient:Narrative {LNC,MTH}) [clna]
<<<< Mappings

Phrase: argue against an independent prognostic role of INK4 deletions
>>>> Phrase
argue against an independent prognostic role of ink4 deletions
<<<< Phrase
>>>> Mappings
Meta Mapping (704):
762 Independent of {CHV,MTH,SNMI,SNOMEDCT_US} [ftcn]
742 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
~~742 Role (Social Role {AOD,CHV,CSP,LCH_NW,MSH,MTH,NCI}) [socb]~~
742 INK4 (CDKN2A wt Allele {MTH,NCI,NLMSubSyn}) [gngm]
708 Deletion (Deletion (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: in relapsed childhood ALL.
>>>> Phrase
relapsed childhood acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 relapsed childhood Acute lymphoblastic leukaemia (recurrent
childhood acute lymphoblastic leukemia {CHV,NCI,NLMSubSyn,PDQ}) [neop]
<<<< Mappings
Processing text_000N_42247.tx.1: PMID: 12036898 [Indexed for MEDLINE]

Phrase: PMID

```
>>>> Phrase  
pmid  
<<<< Phrase
```

```
Phrase: :  
>>>> Phrase  
<<<< Phrase
```

```
Phrase: 12036898  
>>>> Phrase  
12036898  
<<<< Phrase
```

```
Phrase: [Indexed for MEDLINE  
>>>> Phrase  
indexed for medline  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (746):  
    790 indexed (Index {CHV,MSH,MTH,NCI}) [inpr]  
    623 MEDLINE {CHV,LCH_NW,MSH,MTH} [inpr]  
<<<< Mappings
```

```
Phrase: ]  
>>>> Phrase  
<<<< Phrase  
Processing text_000N_41888.tx.1: Phase 1 study of the anti-CD22  
immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic  
leukemia.
```

```
Phrase: Phase 1 study of the anti-CD22 immunotoxin moxetumomab  
pasudotox  
>>>> Phrase  
phase 1 study of the anti cd22 immunotoxin moxetumomab pasudotox  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (747):  
    782 Phase 1 Study (Phase I Clinical Trials  
{CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]  
    615 anti-CD22 immunotoxin (CD22 Immunotoxin {NCI,NCI_NCI-GLOSS})  
[imft,phsu]  
    593 MOXETUMOMAB PASUDOTOX (immunotoxin HA22  
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]  
<<<< Mappings
```

```
Phrase: for childhood acute lymphoblastic leukemia.  
>>>> Phrase  
childhood acute lymphoblastic leukemia  
<<<< Phrase  
>>>> Mappings
```

Meta Mapping (1000):

1000 childhood Acute lymphoblastic leukaemia (Leukemia, Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]
<<<< Mappings

Processing text_000N_19596.tx.1: Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL).

Phrase: Novel therapies

>>>> Phrase

novel therapies

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 novel Therapies (novel AODU treatment method {AOD,NLMSubSyn}) [topp]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: needed

>>>> Phrase

needed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 needed (Patient need for (contextual qualifier) {CHV,MTH,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: overcome

>>>> Phrase

overcome

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Overcome {NCI} [acty]

<<<< Mappings

Phrase: chemotherapy resistance for children

>>>> Phrase

chemotherapy resistance for children

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

604 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]

770 Resistance (Resistance (Psychotherapeutic) {CHV,MTH}) [menp]

604 Children (Child
{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,NDFRT,SNMI,SNOMEDCT_US}) [aggp]

<<<< Mappings

Phrase: with relapsed/refractory acute lymphoblastic leukemia (ALL).

>>>> Phrase

relapsed refractory acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (875):

637 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]

637 Refractory (Unresponsive to Treatment {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [ftcn]

884 Acute lymphoblastic leukaemia (Acute lymphocytic leukemia
{CHV,COSTAR,CSP,CST,HPO,ICD10CM,ICD9CM,MEDLINEPLUS,MTH,NCI,NCI_CDSC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,OMIM,PDO,QMR,SNM,SNOMEDCT_US,SNOMEDCT_VET}) [neop]

<<<< Mappings

Processing text_000N_19596.tx.2: Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin.

Phrase: Moxetumomab pasudotox

>>>> Phrase

moxetumomab pasudotox

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a recombinant anti-CD22 immunotoxin.

>>>> Phrase

recombinant anti cd22 immunotoxin

```
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
    645 recombinant (Recombinants {NCI,NCI_NCI-GLOSS}) [orgm]
    923 anti-CD22 immunotoxin (CD22 Immunotoxin {NCI,NCI_NCI-GLOSS})
    [imft,phsu]
<<<< Mappings
Processing text_000N_19596.tx.3: A multicenter phase 1 study was
conducted to determine the maximum-tolerated cumulative dose (MTCD)
and evaluate safety, activity, pharmacokinetics, and immunogenicity of
moxetumomab pasudotox in children, adolescents, and young adults with
ALL (N = 55).

Phrase: A multicenter phase 1 study
>>>> Phrase
multicenter phase 1 study
<<<< Phrase
>>>> Mappings
Meta Mapping (895):
    562 Multicentric {CHV,NCI,SNOMEDCT_US} [spco]
    923 Phase 1 Study (Phase I Clinical Trials
    {CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [resa]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: conducted
>>>> Phrase
conducted
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
    966 Conduct (Behavior
    {AOD,CHV,CSP,GO,LNC,MSH,MTH,NCI,NCI_NICH,SNM,SNMI,SNOMEDCT_US})
    [bhvr]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: determine
>>>> Phrase
```

determine
<<<< Phrase

Phrase: the maximum-tolerated cumulative dose

>>>> Phrase

maximum tolerated cumulative dose

<<<< Phrase

>>>> Mappings

Meta Mapping (916):

923 Maximum Tolerated Dose {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [qnco]

812 Cumulative {NCI} [qlco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: evaluate

>>>> Phrase

evaluate

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Evaluate (Evaluation

{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHD,NLMSubSyn}) [hlca]

<<<< Mappings

Phrase: safety,

>>>> Phrase

safety

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]

<<<< Mappings

Phrase: activity,

>>>> Phrase

activity

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 ACTIVITY (Activities

{CHV,ICD9CM,LNC,MTH,NCI,NCI_BRIDG,NLMSubSyn,SNOMEDCT_US}) [acty]

<<<< Mappings

Phrase: pharmacokinetics,

>>>> Phrase

pharmacokinetics

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  pharmacokinetics (Pharmacokinetic aspects {MSH,MTH}) [ftcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: immunogenicity of moxetumomab pasudotox
>>>> Phrase
  immunogenicity of moxetumomab pasudotox
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
  770  IMMUNOGENICITY (Immunogenicity Study {NCI,NCI_CDISC}) [resa]
  666  MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]
<<<< Mappings

Phrase: in children,
>>>> Phrase
  children
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Children (Child
{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,
NDFRT,SNMI,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: adolescents,
>>>> Phrase
  adolescents
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Adolescents (Adolescent (age group)
{AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: young adults with ALL
>>>> Phrase
  young adults with acute lymphoblastic leukemia
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (819):
  753  Young {CHV,SNMI,SNOMEDCT_US} [tmco]
  847  Adult Acute lymphoblastic leukaemia (Adult Acute Lymphocytic
Leukemia {MTH,NCI,NLMSubSyn,PDQ}) [neop]
<<<< Mappings

Phrase: (N
>>>> Phrase
n
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  N+ (N+ (tumor staging) {MTH,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: = 55
>>>> Phrase
55
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  55 {SNOMEDCT_US} [inpr]
<<<< Mappings

Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_19596.tx.4: Moxetumomab pasudotox was
administered as a 30-minute IV infusion at doses of 5 to 50 g/kg every
other day for 6 (cohorts A and B) or 10 (cohort C) doses in 21-day
cycles.

Phrase: Moxetumomab pasudotox
>>>> Phrase
moxetumomab pasudotox
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: administered as a 30-minute IV infusion
>>>> Phrase
administered as a 30 minute iv infusion
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (737):
  748 Administered (Having administered {MTH,NCI}) [ftcn]
  778 30 minute (per 30 minutes {CHV,MTH,SNOMEDCT_US}) [tmco]
  778 IV Infusion (Intravenous infusion procedures
{CHV,LNC,MSH,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]
<<<< Mappings
```

Phrase: at doses of 5

```
>>>> Phrase
```

at doses of 5

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (770):

```
  770 Doses (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
```

```
<<<< Mappings
```

Phrase: to 50 g/kg

```
>>>> Phrase
```

50 g kg

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (901):

```
  660 <50 {LNC} [fndg]
  901 g/kg (Gram per Kilogram
{MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [qnco]
```

```
<<<< Mappings
```

Phrase: every other day for 6

```
>>>> Phrase
```

every other day for 6

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (797):

```
  797 Day 6 {LNC} [fndg]
<<<< Mappings
```

Phrase: (cohorts

```
>>>> Phrase
```

cohorts

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

```
  1000 cohorts (Cohort {CHV,CSP,MTH,NCI,NCI_NCI-GLOSS}) [popg]
<<<< Mappings
```

Phrase: A

>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: B)
>>>> Phrase
b
<<<< Phrase

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: 10
>>>> Phrase
10
<<<< Phrase

Phrase: (cohort C
>>>> Phrase
cohort c
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
 694 COHORT (Cohort Studies
 {AOD,CHV,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: doses in 21-day cycles.
>>>> Phrase
doses in 21 day cycles
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
 760 Doses (Dosage
 {CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-
 GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
 614 Cycle day {LNC} [tmco]
<<<< Mappings
Processing text_000N_19596.tx.5: Cohorts B and C received
dexamethasone prophylaxis against capillary leak syndrome (CLS).

Phrase: Cohorts B

```
>>>> Phrase
cohorts b
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
  694  cohorts (Cohort {CHV,CSP,MTH,NCI,NCI_NCI-GLOSS}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: C
>>>> Phrase
C
<<<< Phrase

Phrase: received
>>>> Phrase
received
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  RECEIVED (Receive {NCI,NCI_CDISC}) [qlco]
<<<< Mappings

Phrase: dexamethasone prophylaxis against capillary leak syndrome
(CLSS).
>>>> Phrase
dexamethasone prophylaxis against capillary leak syndrome
<<<< Phrase
>>>> Mappings
Meta Mapping (776):
  586  DEXAMETHASONE (Dexamethasone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_F
DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orch,phsu]
  753  Prophylaxis (Prophylactic treatment
{AOD,CHV,CSP,LCH,MEDLINEPLUS,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NCI_NCI-
HL7,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]
  666  CAPILLARY LEAK SYNDROME (Capillary Leak Syndrome
{CHV,CST,HPO,MSH,MTH,NCI,NCI_CTCAE,NCI_NCI-
GLOSS,NDFRT,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings
Processing text_000N_19596.tx.6: The most common treatment-related
adverse events were reversible weight gain, hepatic transaminase
elevation, and hypoalbuminemia.

Phrase: The most common treatment-related adverse events
>>>> Phrase
```

most common treatment related adverse events

<<<< Phrase
>>>> Mappings
Meta Mapping (827):
632 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
632 Common (shared attribute {MTH,NCI}) [ftcn]
632 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
632 Related (Relationships {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US})
[qlco]
827 Adverse Events (Adverse Event Domain {MTH,NCI,NCI_CDISC})
[inpr]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: reversible weight gain,
>>>> Phrase
reversible weight gain
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
660 Reversible {CHV,SNMI,SNOMEDCT_US} [ftcn]
901 Weight gain (Weight Gain Adverse Event {MTH,NCI,NCI_CTCAE})
[fnndg]
<<<< Mappings

Phrase: hepatic transaminase elevation,
>>>> Phrase
hepatic transaminase elevation
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
660 Hepatic {CSP,LNC,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}
[blor]
660 Transaminase (Transaminases
{AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NDFRT,SNM,SNOMEDCT_US})
[aapp,enz]
827 Elevation {CHV,MTH,NCI,SNOMEDCT_US} [spco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: hypoalbuminemia.

```
>>>> Phrase
hypoalbuminemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Hypoalbuminaemia (Hypoalbuminemia
{AOD,CHV,CSP,CST,DXP,HPO,MSH,MTH,NDFRT,SNOMEDCT_US}) [dsyn]
<<<< Mappings
Processing text_000N_19596.tx.7: Dose-limiting CLS occurred in 2 of 4
patients receiving 30 mcg/kg of moxetumomab pasudotox every other day
for 6 doses.

Phrase: Dose-limiting CLS
>>>> Phrase
dose limiting capillary leak syndrome
<<<< Phrase
>>>> Mappings
Meta Mapping (893):
 673  Dose-Limiting (dose-limiting {CHV,NCI,NCI_NCI-GLOSS}) [idcn]
 884  CAPILLARY LEAK SYNDROME (Capillary Leak Syndrome
{CHV,CST,HPO,MSH,MTH,NCI,NCI_CTCAE,NCI_NCI-
GLOSS,NDFRT,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: occurred in 2 of 4 patients
>>>> Phrase
occurred in 2 of 4 patients
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 753  Occurred (Occur (action) {MTH,NCI}) [acty]
 753  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: receiving
>>>> Phrase
receiving
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  RECEIVING (Receive {NCI,NCI_CDISC}) [qlco]
<<<< Mappings

Phrase: 30 mcg/kg of moxetumomab pasudotox
>>>> Phrase
30 mcg kg of moxetumomab pasudotox
<<<< Phrase
>>>> Mappings
```

Meta Mapping (759):
586 30% {LNC} [qnco]
790 mcg/kg (Microgram per Kilogram
{MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [qnco]
623 MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]
<<<< Mappings

Phrase: every other day for 6 doses.

>>>> Phrase
every other day for 6 doses

<<<< Phrase
>>>> Mappings
Meta Mapping (722):

783 Day 6 {LNC} [fndg]
586 Doses (Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]

<<<< Mappings
Processing text_000N_19596.tx.8: Incorporation of dexamethasone prevented further dose-limiting CLS.

Phrase: Incorporation of dexamethasone

>>>> Phrase
incorporation of dexamethasone

<<<< Phrase
>>>> Mappings
Meta Mapping (746):

790 incorporation {MSH} [ftcn]
623 DEXAMETHASONE (Dexamethasone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orchn,phsu]
<<<< Mappings

Phrase: prevented

>>>> Phrase

prevented

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 PREVENT (PREVENT (product) {CHV,MTH,SNMI,SNOMEDCT_US}) [phsu]
<<<< Mappings

Phrase: further dose-limiting CLS.

>>>> Phrase

further dose limiting capillary leak syndrome

<<<< Phrase

>>>> Mappings

Meta Mapping (864):

632 Further {NCI} [spco]
660 Dose-Limiting (dose-limiting {CHV,NCI,NCI_NCI-GLOSS}) [idcn]
861 CAPILLARY LEAK SYNDROME (Capillary Leak Syndrome
{CHV,CST,HPO,MSH,MTH,NCI,NCI_CTCAE,NCI_NCI-
GLOSS,NDFRT,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings
Processing text_000N_19596.tx.9: Six of 14 patients receiving 50 mcg/
kg of moxetumomab pasudotox for 10 doses developed hemolytic uremic
syndrome (HUS), thrombotic microangiopathy (TMA), or HUS-like events,
exceeding the MTCD.

Phrase: Six of 14 patients

>>>> Phrase

six of 14 patients

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 Six {MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
770 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: receiving

>>>> Phrase

receiving

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 RECEIVING (Receive {NCI,NCI_CDISC}) [qlco]
<<<< Mappings

Phrase: 50 mcg/kg of moxetumomab pasudotox

>>>> Phrase

50 mcg kg of moxetumomab pasudotox

<<<< Phrase

>>>> Mappings

Meta Mapping (759):

586 <50 {LNC} [fndg]
790 mcg/kg (Microgram per Kilogram
{MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [qnco]
623 MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]
<<<< Mappings

Phrase: for 10 doses

>>>> Phrase

10 doses

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 10% {LNC} [qnco]
861 Doses (Dosage)
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: developed

>>>> Phrase

developed

<<<< Phrase

Phrase: hemolytic uremic syndrome (HUS),

>>>> Phrase

hemolytic uremic syndrome

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Haemolytic uraemic syndrome, NOS (Hemolytic-Uremic Syndrome
{CHV,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,MSH,MTH,NCI,NCI_CTCAE,NCI_NICHHD,NDFRT,OMIM,RAM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: thrombotic microangiopathy (TMA),

>>>> Phrase

thrombotic microangiopathy

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Microangiopathy, Thrombotic (Thrombotic Microangiopathies
{CHV,COSTAR,ICD10CM,ICD9CM,MSH,MTH,NCI,NCI_NICHHD,NDFRT,OMIM,SNMI,SNOME_DCT_US}) [dsyn]
<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: HUS-

>>>> Phrase

hemolytic uremic syndrome

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Haemolytic uraemic syndrome, NOS (Hemolytic-Uremic Syndrome
{CHV,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,MSH,MTH,NCI,NCI_CTCAE,NCI_NICHHD,NDFRT,OMIM,RAM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: like events,

```
>>>> Phrase
events
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Events (Event {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [evnt]
<<<< Mappings

Phrase: exceeding
>>>> Phrase
exceeding
<<<< Phrase

Phrase: the MTCD.
>>>> Phrase
maximum tolerated cumulative dose
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
 923  Maximum Tolerated Dose {CHV,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn} [qnco]
 812  Cumulative {NCI} [qlco]
<<<< Mappings
Processing text_000N_19596.tx.10: Treatment expansion at 40 mcg/kg for
10 doses (n = 11) exceeded the MTCD because of 2 HUS/TMA/HUS-like
events.

Phrase: Treatment expansion at 40 mcg/kg
>>>> Phrase
treatment expansion at 40 mcg kg
<<<< Phrase
>>>> Mappings
Meta Mapping (558):
 586  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[ topp ]
 586  40% {LNC} [qnco]
 623  mcg/kg (Microgram per Kilogram
{MTH,NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: for 10 doses
>>>> Phrase
10 doses
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694  10% {LNC} [qnco]
 861  Doses (Dosage
```

```
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]  
<<<< Mappings
```

```
Phrase: (n  
>>>> Phrase  
n  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (1000):  
    1000 N+ (N+ (tumor staging) {MTH,SNOMEDCT_US}) [inpr]  
<<<< Mappings
```

```
Phrase: = 11  
>>>> Phrase  
11  
<<<< Phrase
```

```
Phrase: )  
>>>> Phrase  
<<<< Phrase
```

```
Phrase: exceeded  
>>>> Phrase  
exceeded  
<<<< Phrase
```

```
Phrase: the MTCD because of 2 HUS/TMA/HUS-  
>>>> Phrase  
the maximum tolerated cumulative dose because of 2 hemolytic uremic  
syndrome thrombotic microangiopathy hemolytic uremic syndrome  
<<<< Phrase  
>>>> Mappings  
Meta Mapping (674):  
    755 Maximum Tolerated Dose {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [qnc0]  
    733 Cumulative {NCI} [qlco]  
    590 Haemolytic uraemic syndrome, NOS (Hemolytic-Uremic Syndrome  
{CHV,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,MSH,MTH,NCI,NCI_CTCAE,NCI_NICHDI,NDFRT,OMIM,SNM,SNMI,SNOMEDCT_US}) [dsyn]  
    578 Microangiopathy, Thrombotic (Thrombotic Microangiopathies  
{CHV,COSTAR,ICD10CM,ICD9CM,MSH,MTH,NCI,NCI_NICHDI,NDFRT,OMIM,SNMI,SNOME_DCT_US}) [dsyn]  
<<<< Mappings
```

```
Phrase: like events.  
>>>> Phrase  
events  
<<<< Phrase  
>>>> Mappings
```

Meta Mapping (1000):

1000 Events (Event {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [evnt]

<<<< Mappings

Processing text_000N_19596.tx.11: Dose level 6B (ie, 50 mcg/kg 6 doses) was the MTCD, selected as the recommended phase 2 dose.

Phrase: Dose level 6B

>>>> Phrase

dose level 6b

<<<< Phrase

>>>> Mappings

Meta Mapping (734):

734 Dose Level (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDSC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: ie

>>>> Phrase

<<<< Phrase

Phrase: ,

>>>> Phrase

<<<< Phrase

Phrase: 50 mcg/kg 6 doses

>>>> Phrase

50 mcg kg 6 doses

<<<< Phrase

>>>> Mappings

Meta Mapping (785):

637 <50 {LNC} [fndg]

686 MCG-6 {NCBI} [arch]

804 Doses (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDSC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]

Meta Mapping (840):

637 <50 {LNC} [fndg]

686 MCG-6 {NCBI} [arch]

637 kg (Kilogram {CHV,MTH,NCI,NCI_CDSC,NCI_FDA,NCI_ICH,NCI_NCI-GLOSS,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [qnc0]

804 Doses (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDSC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnc0]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: the MTCD,
>>>> Phrase
maximum tolerated cumulative dose
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
 923 Maximum Tolerated Dose {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [qnco]
 812 Cumulative {NCI} [qlco]
<<<< Mappings

Phrase: selected as the recommended phase 2 dose.

>>>> Phrase
selected as the recommended phase 2 dose
<<<< Phrase
>>>> Mappings
Meta Mapping (719):
 748 Selected (Choose (action) {CHV,LNC,MTH,NCI}) [acty]
 748 Recommended (Recommendation {CHV,HL7V3.0,LNC,MTH,NCI}) [idcn]
 778 Phase 2 {CHV,NLMSubSyn,SNOMEDCT_US} [tmco]
 748 DOSE (Dosage)
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_19596.tx.12: Among 47 evaluable patients, an objective response rate of 32% was observed, including 11 (23%) composite complete responses, 5 of which were minimal residual disease negative by flow cytometry.

Phrase: Among 47 evaluable patients,
>>>> Phrase
47 evaluable patients
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 901 evaluable patients (Evaluable Patient {NCI,NCI_NCI-GLOSS,NLMSubSyn}) [podg]
<<<< Mappings

Phrase: an objective response rate of 32%
>>>> Phrase
an objective response rate of 32

```
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
  753 Objective (objective (goal)
  tAOD,CHV,LNC,MSH,MTH,NCI,SNOMEDCT_US}) [input]
  790 Response Rate (Frequency of Responses {CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn}) [tmco]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: observed
>>>> Phrase
observed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Observed {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: including
>>>> Phrase
including
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Including (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: 11
>>>> Phrase
11
<<<< Phrase

Phrase: (23%
>>>> Phrase
23
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 23 {MTH,NCI,SNOMEDCT_US} [qnco]
<<<< Mappings
```

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: composite complete responses,
>>>> Phrase
composite complete responses
<<<< Phrase
>>>> Mappings
Meta Mapping (884):
660 Composite {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
867 Complete Response (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fndg]
<<<< Mappings

Phrase: 5 of which
>>>> Phrase
5 of which
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
790 >5 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: minimal residual disease negative by flow cytometry.
>>>> Phrase
minimal residual disease negative by flow cytometry
<<<< Phrase
>>>> Mappings
Meta Mapping (811):
853 Minimal Residual Disease Negative (Minimal Residual Disease
Negativity {NCI,NCI_CDISC}) [fndg]
612 FLOW CYTOMETRY (Flow Cytometry
{CHV,CSP,LCH,LCH_NW,LNC,MSH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,PDQ,SNMI,SNOMEDCT_US}) [lbpr]
<<<< Mappings
Processing text_000N_19596.tx.13: Moxetumomab pasudotox showed a
manageable safety profile and evidence of activity in relapsed or
refractory childhood ALL.

Phrase: Moxetumomab pasudotox
>>>> Phrase
moxetumomab pasudotox
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 MOXETUMOMAB PASUDOTOX (immunotoxin HA22
{DRUGBANK,MSH,NCI,NCI_FDA}) [aapp,imft,phsu]
<<<< Mappings

Phrase: showed
>>>> Phrase
showed
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
966 Show {HL7V2.5,HL7V3.0} [anim]
<<<< Mappings

Phrase: a manageable safety profile
>>>> Phrase
manageable safety profile
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
660 SAFETY (Safety Study {MTH,NCI,NCI_CDISC}) [resa]
827 ~~Profile (Profile (lab procedure) {LNC,MTH}) [lbpr]~~
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: evidence of activity
>>>> Phrase
evidence of activity
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
790 Evidence {NCI} [idcn]
623 ACTIVITY (Activities
{CHV,ICD9CM,LNC,MTH,NCI,NCI_BRIDG,NLMSubSyn,SNOMEDCT_US}) [acty]
<<<< Mappings

Phrase: in relapsed
>>>> Phrase
relapsed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: or
>>>> Phrase

<<<< Phrase

Phrase: refractory childhood ALL.

>>>> Phrase

refractory childhood acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Refractory Childhood Acute Lymphoblastic Leukemia {NCI}
 [neop]

<<<< Mappings

Processing text_000N_19596.tx.14: This trial was registered at

www.clinicaltrials.gov as NCT00659425.

Phrase: This trial

>>>> Phrase

trial

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Trial (Clinical Trials
 {AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NC
 I-GLOSS,SNOMEDCT_US}) [resa]

<<<< Mappings

Phrase: was

>>>> Phrase

<<<< Phrase

Phrase: registered at www.clinicaltrials.gov

>>>> Phrase

registered at www clinicaltrials gov

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

 760 Registered (Registration {MTH,NCI}) [hlca]
 760 WWW (Internet {AOD,CHV,CSP,LCH_NW,MSH,MTH,NCI,NCI_CDISC})
 [mnobj]

 806 ClinicalTrials.gov {NCI} [inpr]

<<<< Mappings

Phrase: as NCT00659425.

>>>> Phrase

nct00659425

<<<< Phrase

Processing text_000N_42008.tx.1: PMID: 28983018 [Indexed for MEDLINE]

Phrase: PMID

>>>> Phrase

pmid

<<<< Phrase

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: 28983018
>>>> Phrase
28983018
<<<< Phrase

Phrase: [Indexed for MEDLINE]
>>>> Phrase
indexed for medline
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 indexed (Index {CHV,MSH,MTH,NCI}) [inpr]
 623 MEDLINE {CHV,LCH_NW,MSH,MTH} [inpr]
<<<< Mappings

Phrase:]
>>>> Phrase
<<<< Phrase
Processing text_000N_41968.tx.1: The t(12;21)(p13;q22) in Pediatric B-Acute Lymphoblastic Leukemia: An Update.

Phrase: The t(12
>>>> Phrase
t 12
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 T' (T prime {LNC,MTH}) [clna]
<<<< Mappings

Phrase: ;21
>>>> Phrase
21
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: (p13
>>>> Phrase
p13
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 p13 (MTCP1 gene {HGNC,MTH,NCI,OMIM}) [gngm]
<<<< Mappings

Phrase: ;q22
>>>> Phrase
q22
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: in Pediatric B-Acute Lymphoblastic Leukemia
>>>> Phrase
pediatric b acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (933):
933 pediatric Acute lymphoblastic leukaemia (Leukemia, Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]
<<<< Mappings

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: An Update.
>>>> Phrase
update
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Update {MTH,NCI} [tmco]
<<<< Mappings
Processing text_000N_30691.tx.1: Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy in children, and the t(12;21)(p13;q22) occurs in approximately 25% of these cases, making it is the most prevalent chromosomal abnormality.

Phrase: Pediatric B-cell acute lymphoblastic leukemia
>>>> Phrase
pediatric b cell acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (938):
632 paediatric (Pediatrics {CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]
947 B Cell Acute lymphoblastic leukemia (Precursor B-cell

lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: the most common hematological malignancy in children,
>>>> Phrase

the most common hematological malignancy in children

<<<< Phrase

>>>> Mappings

Meta Mapping (719):

581 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

581 Common (Common (qualifier value)

{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qnco]

778 Malignancy, Hematological (Hematologic Neoplasms

{CHV,CSP,HPO,MSH,MTH,NCI,NCI_NCI-

GLOSS,NDFRT,NLMSubSyn,PDQ,SNOMEDCT_US}) [neop]

581 Children (Offspring

{AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]

<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: the t(12

>>>> Phrase

t 12

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 T' (T prime {LNC,MTH}) [clna]

<<<< Mappings

Phrase: ;21
>>>> Phrase
21
<<<< Phrase

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: (p13

>>>> Phrase

p13

<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  p13 (MTCP1 gene {HGNC,MTH,NCI,OMIM}) [gngm]
<<<< Mappings

Phrase: ;q22
>>>> Phrase
q22
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: occurs in approximately 25% of these cases,
>>>> Phrase
occurs in approximately 25 of these cases
<<<< Phrase
>>>> Mappings
Meta Mapping (652):
  748  Occur (Occur (action) {MTH,NCI}) [acty]
  748  Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
  [qlco]
  748  Cases (Case unit dose {MTH,NCI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: making
>>>> Phrase
making
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Make (Make - Instruction Imperative {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: the most prevalent chromosomal abnormality.
>>>> Phrase
most prevalent chromosomal abnormality
<<<< Phrase
>>>> Mappings
Meta Mapping (843):
  645  Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
```

574 Prevalences (Statistical Prevalence
{AOD,CHV,CSP,MSH,MTH,NCI}) [qnco]
861 Chromosomal Abnormality (Congenital chromosomal disease
{CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME
DCT_US}) [cgab,dsyn]

<<<< Mappings

Processing text_000N_30691.tx.2: The t(12;21) which disrupts
hematopoietic differentiation and proliferation, and can be present as
a sole abnormality or within the context of a complex karyotype
characterized by three or more chromosomal abnormalities.

Phrase: The t(12

>>>> Phrase

t 12

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 T' (T prime {LNC,MTH}) [clna]

<<<< Mappings

Phrase: ;21

>>>> Phrase

21

<<<< Phrase

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: which

>>>> Phrase

<<<< Phrase

Phrase: disrupts

>>>> Phrase

disrupts

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 disrupts (disrupted {CHV,SNMI}) [qlco]

<<<< Mappings

Phrase: hematopoietic differentiation

>>>> Phrase

hematopoietic differentiation

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Haematopoietic (Hematopoietic System

{AOD,CHV,FMA,LCH,LCH_NW,MSH,MTH,NCI,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]

861 Differentiation (Cell Differentiation process
{AOD,CHV,CSP,GO,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})
[celf]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: proliferation,
>>>> Phrase
proliferation
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Proliferation (Proliferation (morphologic abnormality)
{CHV,MTH,SNM,SNMI,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: present as a sole abnormality
>>>> Phrase
present as a sole abnormality
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 760 PRESENT (Present
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]
 593 SOLE (Sole of Foot
{AOD,CHV,FMA,HL7V2.5,MTH,NCI,NCI_CDISC,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_V
ET,UWDA}) [blor]
 593 Abnormality {MTH,NCI} [fndg]
<<<< Mappings

Phrase: or within the context of a complex karyotype
>>>> Phrase
or within the context of a complex karyotype
<<<< Phrase
>>>> Mappings

Meta Mapping (694):
744 context (contextual factors {AOD,CHV,MTH}) [menp]
770 Complex Karyotype {NCI} [comd]
<<<< Mappings

Phrase: characterized by three

>>>> Phrase
characterized by three

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 Characterized (Characterization {NCI}) [acty]
790 Three {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: or

>>>> Phrase
<<<< Phrase

Phrase: more chromosomal abnormalities.

>>>> Phrase
more chromosomal abnormalities

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

660 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
901 Abnormalities, Chromosomal (Congenital chromosomal disease {CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME DCT_US}) [cgab,dsyn]

<<<< Mappings

Processing text_000N_30691.tx.3: The prognosis of t(12;21) within a complex karyotype is extensively debated.

Phrase: The prognosis of t(12

>>>> Phrase
the prognosis of t 12

<<<< Phrase

>>>> Mappings

Meta Mapping (760):

760 Prognosis (Forecast of outcome {AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]

<<<< Mappings

Phrase: ;21

>>>> Phrase
21
<<<< Phrase

Phrase:)

```
>>>> Phrase
<<<< Phrase

Phrase: within a complex karyotype
>>>> Phrase
complex karyotype
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Complex Karyotype {NCI} [comd]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: extensively
>>>> Phrase
extensively
<<<< Phrase

Phrase: debated.
>>>> Phrase
debated
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
    966  debate {CHV} [acty]
<<<< Mappings
Processing text_000N_30691.tx.4: In this review, we discuss the literature regarding t(12;21) and summarize the cytogenetic features found in 363 pediatric cases compiled from the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer.

Phrase: In this review,
>>>> Phrase
review
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Review (Act Class - review {HL7V3.0,MTH,NCI}) [idcn]
<<<< Mappings

Phrase: we
>>>> Phrase
<<<< Phrase

Phrase: discuss
>>>> Phrase
discuss
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Discuss (Discussion (communication) {ICF,ICF-CY,MTH,NCI})
  [socb]
<<<< Mappings

Phrase: the literature regarding t(12
>>>> Phrase
literature regarding t 12
<<<< Phrase
>>>> Mappings
Meta Mapping (645):
  645  Literature {AOD,CHV,HL7V2.5,LCH,LCH_NW,MSH,MTH} [inpr]
<<<< Mappings

Phrase: ;21
>>>> Phrase
21
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: summarize
>>>> Phrase
summarize
<<<< Phrase

Phrase: the cytogenetic features
>>>> Phrase
cytogenetic features
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
  694  Cytogenetic (Cytogenetics
  {AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,NCI,NCI_NCI-GLOSS}) [bmod]
  827  Feature (Image Feature {MTH,NCI,NLMSubSyn}) [qlco]
<<<< Mappings

Phrase: found in 363 pediatric cases
>>>> Phrase
found in 363 pediatric cases
<<<< Phrase
>>>> Mappings
```

Meta Mapping (696):
760 Found (Present {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[fndg]
760 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
760 Cases (Case unit dose {MTH,NCI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: compiled from the Mitelman Database of Chromosome Aberrations
>>>> Phrase

compiled from the mitelman database of chromosome aberrations

<<<< Phrase

>>>> Mappings

Meta Mapping (682):

744 data base (Databases {AOD,CHV,CSP,MTH,NCI}) [inpr]
770 Chromosome Aberrations (Congenital chromosomal disease
{CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME
DCT_US}) [cgab,dsyn]

Meta Mapping (694):

744 Database (Published Database {LCH_NW,MSH,MTH}) [inpr]
770 Chromosome Aberrations (Congenital chromosomal disease
{CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME
DCT_US}) [cgab,dsyn]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: Gene Fusions in Cancer.

>>>> Phrase

gene fusions in cancer

<<<< Phrase

>>>> Mappings

Meta Mapping (881):

881 cancer gene Fusions (Oncogene Fusion {MSH,NLMSubSyn}) [comd]

<<<< Mappings

Processing text_000N_30691.tx.5: Cytogenetically, most of the cases
had secondary chromosomal abnormalities, about half of which were in
the context of a complex karyotype.

Phrase: Cytogenetically,

>>>> Phrase

cytogenetically

<<<< Phrase

Phrase: most of the cases

>>>> Phrase

most of the cases

```
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
    770    Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
    770    Cases (Case unit dose {MTH,NCI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: had
>>>> Phrase
<<<< Phrase

Phrase: secondary chromosomal abnormalities,
>>>> Phrase
secondary chromosomal abnormalities
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
    660    secondary (Neoplasm Metastasis
{AOD,CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,NLMSubSyn}
[neop]
    901    Abnormalities, Chromosomal (Congenital chromosomal disease
{CHV,CSP,CST,ICD10CM,ICD9CM,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNM,SNMI,SNOME
DCT_US}) [cgab,dsyn]
<<<< Mappings

Phrase: about half of which
>>>> Phrase
about half of which
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
    770    About (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US}) [qlco]
    770    Half {MTH,NCI,NCI_CDISC} [qnco]
<<<< Mappings

Phrase: were in the context of a complex karyotype.
>>>> Phrase
were in the context of a complex karyotype
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
    744    context (contextual factors {AOD,CHV,MTH}) [menp]
    770    Complex Karyotype {NCI} [comd]
<<<< Mappings
Processing text_000N_30691.tx.6: Trisomy 21 was found to be the most
common numerical abnormality in almost one-fifth of the cases, and
deletions on chromosome 12 and 6 occurred in 16.9% and 12.5% of cases,
respectively.
```

Phrase: Trisomy 21

```
>>>> Phrase

<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  TRISOMY 21 (Down Syndrome
{AOD,CHV,COSTAR,CSP,CST,DXP,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,MEDLINEPLUS,
MSH,MTH,MTHICD9,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NDFRT,OMIM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: found
>>>> Phrase
found
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Found (Present {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[fndg]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: the most common numerical abnormality in almost one-fifth of
the cases,
>>>> Phrase
the most common numerical abnormality in almost one fifth of the cases
<<<< Phrase
>>>> Mappings
Meta Mapping (658):
  570  Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnc]
  570  Common (Common (qualifier value)
{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qnc]
  570  Numerical (Numbers
```

```
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_UCUM,SNMI,SNOMEDCT_US}) [qnc0]
736 Abnormality {MTH,NCI} [fndg]
570 Almost (Nearly {NCI}) [qlco]
570 ONE (One {LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnc0]
570 Fifth {LNC,NCI,SNMI,SNOMEDCT_US} [qnc0]
570 Cases (Case unit dose {MTH,NCI,SNOMEDCT_US}) [qnc0]
```

```
<<<< Mappings
```

Phrase: and

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: deletions on chromosome 12

```
>>>> Phrase
```

```
deletions on chromosome 12
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (819):

```
819 Deletions, Chromosome (Chromosome Deletion
```

```
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNOMEDCT_US}) [comd]
```

```
<<<< Mappings
```

Phrase: and

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: 6

```
>>>> Phrase
```

```
6
```

```
<<<< Phrase
```

Phrase: occurred in 16.9%

```
>>>> Phrase
```

```
occurred in 16 9
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (770):

```
770 Occurred (Occur (action) {MTH,NCI}) [acty]
```

```
<<<< Mappings
```

Phrase: and

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: 12.5% of cases,

```
>>>> Phrase
```

```
12 5 of cases
```

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (783):

```
833 12.5 {SNOMEDCT_US} [qnc]
770 Cases (Case unit dose {MTH,NCI,SNOMEDCT_US}) [qnc]
<<<< Mappings
```

Phrase: respectively.

```
>>>> Phrase
```

respectively

```
<<<< Phrase
```

Processing text_000N_30691.tx.7: In general, t(12;21) in B-ALL is associated with a favorable prognosis.

Phrase: In general, t(12

```
>>>> Phrase
```

general t 12

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (660):

660 General (Generalized

```
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
```

```
<<<< Mappings
```

Phrase: ;21

```
>>>> Phrase
```

21

```
<<<< Phrase
```

Phrase:)

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: in B-ALL

```
>>>> Phrase
```

b cell acute lymphoblastic leukemia

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (1000):

1000 B Cell Acute lymphoblastic leukemia (Precursor B-cell lymphoblastic leukemia {CHV,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [neop]

```
<<<< Mappings
```

Phrase: is

```
>>>> Phrase
```

```
<<<< Phrase
```

Phrase: associated with a favorable prognosis.

```
>>>> Phrase
```

associated with a favorable prognosis

```
<<<< Phrase
```

```
>>>> Mappings
```

Meta Mapping (779):

806 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
806 Favorable prognosis (Prognosis good
{CHV,OMIM,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Processing text_000N_30691.tx.8: Herein, we found no significant difference in survival outcome of t(12;21) with a on-complex or complex karyotype.

Phrase: Herein,

>>>> Phrase

herein

<<<< Phrase

Phrase: we

>>>> Phrase

<<<< Phrase

Phrase: found

>>>> Phrase

found

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Found (Present {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[fndg]

<<<< Mappings

Phrase: no significant difference in survival outcome of t(12

>>>> Phrase

no significant difference in survival outcome of t 12

<<<< Phrase

>>>> Mappings

Meta Mapping (640):

742 Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
742 Difference (Different {MTH,NCI}) [qlco]
575 survival (survival aspects {MSH,MTH,NLMSubSyn}) [ftcn]
575 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: ;21

>>>> Phrase

21

<<<< Phrase

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: with a on-complex
>>>> Phrase
on complex
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 On (On (qualifier value) {MTH,SNOMEDCT_US}) [inpr]
861 Complex (complex (molecular entity) {LNC,MTH,NCI}) [chvs]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: complex karyotype.
>>>> Phrase
complex karyotype
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 N Complex Karyotype {NCI} [comd]
<<<< Mappings
Processing text_000N_42088.tx.1: PMID: 28809761

Phrase: PMID
>>>> Phrase
pmid
<<<< Phrase

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: 28809761
>>>> Phrase
28809761
<<<< Phrase
Processing text_000N_1853.tx.1: Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.

Phrase: Treatment of Childhood Acute Lymphoblastic Leukemia
>>>> Phrase
treatment of childhood acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (842):
753 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

716 childhood Acute lymphoblastic leukaemia (Leukemia, Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]
<<<< Mappings

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: Prognostic Factors

>>>> Phrase
prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Clinical Advances.

>>>> Phrase
clinical advances
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
 694 Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
 827 Advance (Advance -- medical device {CHV,MTH}) [medd]
<<<< Mappings
Processing text_000N_23108.tx.1: While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20% of patients will experience relapse.

Phrase: While
>>>> Phrase
<<<< Phrase

Phrase: the majority of children

>>>> Phrase
the majority of children
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 majority {AOD,CHV} [socb]
 604 Children (Child
 {AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,
 NDFRT,SNMI,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: adolescents with newly diagnosed childhood acute lymphoblastic leukemia

>>>> Phrase

adolescents with newly diagnosed childhood acute lymphoblastic leukemia

<<<< Phrase

>>>> Mappings

Meta Mapping (796):

744 Adolescents (Adolescent (age group) {AOD,CHV,DXP,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
578 newly {CHV} [idcn]
578 Diagnosed (Diagnosis {AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
666 childhood Acute lymphoblastic leukaemia (Leukemia, Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]

<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: cured

>>>> Phrase

cured

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Cured (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS})

[cnce]

<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: as
>>>> Phrase
<<<< Phrase

Phrase: many as 20% of patients

```
>>>> Phrase
many as 20 of patients
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
  760  20% {LNC} [qnc0]
  760  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: will
>>>> Phrase
<<<< Phrase

Phrase: experience
>>>> Phrase
experience
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Experience {CHV,CSP,MTH,NCI} [menp]
<<<< Mappings

Phrase: relapse.
>>>> Phrase
relapse
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings
Processing text_000N_23108.tx.2: On current treatment regimens, the
intensity of upfront treatment is stratified based upon prognostic
factors with the aim of improving cure rates (for those at the highest
risk of relapse) and minimizing treatment-related morbidity (for
lower-risk patients).

Phrase: On current treatment regimens,
>>>> Phrase
current treatment regimens
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
  734  Current Treatment (Current Therapy {NCI,NCI_CDISC,NLMSubSyn})
[ topp]
  827  regimens (Regimen – CHV concept {CHV,MTH}) [inpr]
<<<< Mappings

Phrase: the intensity of upfront treatment
```

```
>>>> Phrase
the intensity of upfront treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (797):
    797  treatment intensity (care by level of intensity {AOD}) [qlco]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: stratified
>>>> Phrase
stratified
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Stratified {CHV,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: based upon prognostic factors
>>>> Phrase
based upon prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
    770  Based (Base - General Qualifier {MTH,NCI}) [idcn]
    833  Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings

Phrase: with the aim of improving cure rates
>>>> Phrase
with the aim of improving cure rates
<<<< Phrase
>>>> Mappings
Meta Mapping (665):
    748  Aim (Aim (idea) {MTH,NCI}) [idcn]
    581  Improving (Improving (qualifier value) {CHV,MTH,SNOMEDCT_US})
[qlco]
    581  Cure (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [cnce]
    548  Rate {LNC,MTH,NCI} [qnco]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: for those at the highest risk of relapse
>>>> Phrase
```

```
for those at the highest risk of relapse
<<<< Phrase
>>>> Mappings
Meta Mapping (738):
    783  High risk of {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}
[fndg]
    578  relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: minimizing treatment-related morbidity
>>>> Phrase
minimizing treatment related morbidity
<<<< Phrase
>>>> Mappings
Meta Mapping (775):
    645  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
    645  Related (Related personal status {CHV,MTH,SNOMEDCT_US})
[fndg]
    812  morbidity (morbidity aspects {MSH,MTH}) [inpr]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: for lower-risk patients
>>>> Phrase
lower risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (890):
    717  LOW RISK (Low Risk {LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US})
[qnco]
    827  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: ).
```

```
>>>> Phrase
<<<< Phrase
Processing text_000N_23108.tx.3: Here we review advances in the
understanding of prognostic factors and their application.

Phrase: Here
>>>> Phrase
here
<<<< Phrase

Phrase: we
>>>> Phrase
<<<< Phrase

Phrase: review
>>>> Phrase
review
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Review (Act Class - review {HL7V3.0,MTH,NCI}) [idcn]
<<<< Mappings

Phrase: advances in the understanding of prognostic factors
>>>> Phrase
advances in the understanding of prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (681):
  714  Advance (Advance -- medical device {CHV,MTH}) [medd]
  581  Understanding (Comprehension
{AOD,CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,SNM,SNMI,SNOMEDCT_US})
[memp]
  612  Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: their application.
>>>> Phrase
application
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Application (Application procedure
{CHV,MTH,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings
Processing text_000N_23108.tx.4: We also highlight novel treatment
```

approaches aimed at improving outcomes in childhood ALL.

Phrase: We
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: highlight
>>>> Phrase
highlight
<<<< Phrase

Phrase: novel treatment approaches

>>>> Phrase
novel treatment approaches
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 734 novel Treatment (novel AODU treatment method {AOD,NLMSubSyn})
 [topp]
 827 Approaches (Approach {CHV,MTH,NCI,SNOMEDCT_US}) [spco]
<<<< Mappings

Phrase: aimed at improving outcomes

>>>> Phrase
aimed at improving outcomes
<<<< Phrase
>>>> Mappings
Meta Mapping (711):
 737 Aim (Aim (idea) {MTH,NCI}) [idcn]
 770 Improving (Improving (qualifier value) {CHV,MTH,SNOMEDCT_US})
 [qlco]
 737 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
 GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: in childhood ALL.

>>>> Phrase
childhood acute lymphoblastic leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 childhood Acute lymphoblastic leukaemia (Leukemia,
 Lymphocytic, Acute, L1 {MSH,NCI,NCI_NICHD,NLMSubSyn,PDQ}) [neop]
<<<< Mappings
Processing text_000N_42168.tx.1: PMID: 27502091 [Indexed for MEDLINE]

Phrase: PMID
>>>> Phrase
pmid
<<<< Phrase

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: 27502091
>>>> Phrase
27502091
<<<< Phrase

Phrase: [Indexed for MEDLINE
>>>> Phrase
indexed for medline
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 indexed (Index {CHV,MSH,MTH,NCI}) [inpr]
 623 MEDLINE {CHV,LCH_NW,MSH,MTH} [inpr]
<<<< Mappings

Phrase:]
>>>> Phrase
<<<< Phrase